The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2006
Filed:
Feb. 23, 2004
Jack A. Roth, Houston, TX (US);
Toshiyoshi Fujiwara, Okayama, JP;
Elizabeth A. Grimm, Houston, TX (US);
Tapas Mukhopadhyay, Houston, TX (US);
Wei-wei Zhang, Houston, TX (US);
Laurie B. Owen-schaub, Houston, TX (US);
Jack A. Roth, Houston, TX (US);
Toshiyoshi Fujiwara, Okayama, JP;
Elizabeth A. Grimm, Houston, TX (US);
Tapas Mukhopadhyay, Houston, TX (US);
Wei-Wei Zhang, Houston, TX (US);
Laurie B. Owen-Schaub, Houston, TX (US);
Board of Regents, the University of Texas System, Austin, TX (US);
Abstract
The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.